Science Explorer Interactive view Map
Company · Rotterdam · Netherlands

Pharmerit (Netherlands)

pharmerit.comROR OpenAlex
Research works
113
▼ 40% vs 2013–17
Citations
1.2k
10.5 per fractional work
Top-10% rate
13.6%
record average 16.5%
Open access
36%
world 28%

Not ranked overall: Pharmerit (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Pharmerit (Netherlands)?

Ranked on the composite score, Ling‐Hsiang Chuang, Sonja Kroep and Bart Heeg lead among researchers whose main affiliation is Pharmerit (Netherlands).

  1. 1 Ling‐Hsiang Chuang Netherlands · #662,745 worldwide 38 citations · 31 works
  2. 2 Sonja Kroep Netherlands · #1,225,497 worldwide 19 citations · 18 works
  3. 3 Bart Heeg Netherlands · #1,340,209 worldwide 26 citations · 31 works
All ranked researchers at Pharmerit (Netherlands)

Which keywords describe research at Pharmerit (Netherlands)?

By fractional works in all years, weighted toward what it does more of than the world: Quality of Life, Cost-effectiveness Analysis, Health Utility Measures, Prognostic Factors, Pharmaceutical Industry, Clinical Trials, Treatment and Drug Development Costs.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Quality of Life18▲ 12×13 topics
  2. Cost-effectiveness Analysis14▲ 158×1 topic
  3. Health Utility Measures14▲ 158×1 topic
  4. Epidemiology11▲ 2.3×34 topics
  5. Treatment8▲ 5.2×12 topics
  6. Prognostic Factors7▲ 14×7 topics
  7. Pharmaceutical Industry7▲ 156×2 topics
  8. Clinical Trials7▲ 9.8×6 topics
  9. Drug Development Costs6▲ 207×1 topic
  10. Generic Drugs6▲ 207×1 topic
  11. Clinical Guidelines6▲ 16×6 topics
  12. Immunotherapy5▲ 7.0×6 topics
  13. Cost of Care4▲ 197×1 topic
  14. Financial Toxicity4▲ 197×1 topic
  15. Genetic Mutations4▲ 6.2×4 topics
  16. Glycemic Control4▲ 23×3 topics
  17. Insulin Therapy4▲ 29×3 topics
  18. Immune Response3▲ 4.9×7 topics
  19. Medication Adherence3▲ 52×2 topics
  20. Antiretroviral Therapy3▲ 13×4 topics
  21. Diabetes3▲ 5.6×6 topics
  22. Molecular Characterization3▲ 15×3 topics
  23. Adverse Drug Reactions3▲ 41×2 topics
  24. Publication Bias3▲ 48×2 topics
  25. Asthma3▲ 19×2 topics
  26. Metastatic3▲ 39×1 topic
  27. Renal Cell Carcinoma3▲ 75×1 topic
  28. Guidelines3▲ 5.0×8 topics
  29. Off-Label Drug Use3▲ 63×1 topic
  30. Pediatric Pharmacokinetics3▲ 63×1 topic
  31. Rituximab3▲ 15×2 topics
  32. Type 2 Diabetes3▲ 12×3 topics
  33. Minimal Residual Disease2▲ 31×2 topics
  34. Antiviral Therapy2▲ 13×2 topics
  35. Cardiovascular Outcomes2▲ 46×1 topic
  36. Glucose Control2▲ 46×1 topic
  37. HIV Infection2▲ 16×2 topics
  38. Liver Disease2▲ 14×2 topics
  39. Hepatitis C Virus2▲ 34×1 topic
  40. Ribavirin2▲ 34×1 topic

Which research topics does Pharmerit (Netherlands) publish most on?

By volume in 2022–2025: Esophageal Cancer Research and Treatment, Economic and Financial Impacts of Cancer, Lung Cancer Treatments and Mutations and Health Systems, Economic Evaluations, Quality of Life.

Esophageal Cancer Resear…1Esophageal Cancer Research and Treatment: 1 fractional worksEconomic and Financial Impacts of Cancer: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksHealth Systems, Economic…0Health Systems, Economic Evaluations, Quality of Life: 0 fractional worksBreast Cancer Treatment …0Breast Cancer Treatment Studies: 0 fractional worksHeterotopic Ossification and Related Conditions: 0 fractional worksPharmaceutical studies and practices: 0 fractional worksCystic Fibrosis Research Advances: 0 fractional worksInhalation and Respiratory Drug Delivery: 0 fractional worksCancer survivorship and care: 0 fractional works
SurgeryEconomics and EconometricsPulmonary and Respiratory MedicineCancer Research3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Esophageal Cancer Research and Treatment Surgery 1 works
  2. 2 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
  3. 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  4. 4 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  5. 5 Breast Cancer Treatment Studies Cancer Research 0 works
  6. 6 Heterotopic Ossification and Related Conditions Rheumatology 0 works
  7. 7 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 0 works
  8. 8 Cystic Fibrosis Research Advances Pulmonary and Respiratory Medicine 0 works
  9. 9 Inhalation and Respiratory Drug Delivery Pulmonary and Respiratory Medicine 0 works
  10. 10 Cancer survivorship and care Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available36.2%not open63.8%

World: 28% of research is openly available.

with international co-authors61.6%domestic only38.4%

World: 19% is written across borders.

How has Pharmerit (Netherlands)'s research output changed?

Output in 2018–2022 was 40% lower than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Rotterdam

All research institutions in Rotterdam

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.